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Abstract
Background: Primary diffuse large B-cell lymphoma of the central nervous system (PCNS-DLBCL) is a distinct
clinicopathological entity with a poor prognosis. Concurrent MYC and BCL2 overexpression predicts inferior prognosis
in systemic DLBCLs. However, the prognostic significance of MYC and BCL2 in PCNS-DLBCL remains elusive.
Methods: Immunohistochemistry (IHC) of MYC, BCL2 and BCL6 was performed on tumor samples from 114 patients
with PCNS-DLBCL. IHC score was assigned based on the proportion of immunostained cells.
Results: MYC, BCL2, and BCL6 IHC scores were 18.16 ± 19.58, 58.86 ± 35.07, and 39.39 ± 37.66 % (mean ± SD),
respectively. Twenty-one cases (18.1 %) were designated as MYC-positive with a cutoff score of 40. BCL2 positivity was
found in 87 cases (75.0 %) using a cutoff score of 30. MSKCC (Memorial Sloan-Kettering Cancer Center prognostic
model) class 2 and 3 had higher rates of MYC and/or BCL2 positivity (MYC, P = 0.012; BCL2, P = 0.008; dual-positive,
P = 0.022). Poor KPS (Karnofsky Performance Status score <70), multifocal disease, Nottingham-Barcelona score ≥2, and
MSKCC class 2 and 3 were related to shorter progression-free survival (PFS) (P = 0.001, 0.037, 0.001, and 0.008,
respectively). Patients with older age (>60 years) showed poorer overall survival (OS) (P = 0.020). MYC positivity was
associated with poor PFS (P = 0.027), while patients with BCL2 positivity exhibited a shorter OS (P = 0.010). Concomitant
MYC and BCL2 positivity was related to poor PFS (P = 0.041), while the lack of both MYC and BCL2 expression was
related to prolonged OS (P = 0.014). MYC and BCL2 expression had no independent prognostic implication by
multivariate analysis in overall patients with PCNS-DLBCL. However, among patients treated with combined high-dose
methotrexate, vincristine and procarbazine and radiotherapy, dual MYC and BCL2 overexpression (a cutoff score of 60)
was an independent poor prognostic indicator (P = 0.010).
Conclusions: Evaluation of MYC and BCL2 expression may be helpful for the determination of PCNS-DLBCL prognosis.
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Background
Primary diffuse large B-cell lymphoma of the central
nervous system (PCNS-DLBCL) is a distinct subtype of
DLBCL that primarily arises in the intracranial and in-
traocular areas [1]. PCNS-DLBCL has a poorer progno-
sis than systemic DLBCL. This may be due to the fact
the blood brain barrier makes it difficult for chemother-
apeutic agents to penetrate, that the site of involvement
is immune-privileged, and that the cell of origin is
mainly a non-germinal center B-cell [2].
To determine the prognosis of PCNS-DLBCL, several
scoring systems, which are mostly based on clinical fea-
tures, have been recommended. The international extra-
nodal lymphoma study group (IELSG) suggested that
age (>60 years), performance status (PS) (≥2), elevated
serum lactate dehydrogenase (LDH) levels, a high cere-
brospinal fluid (CSF) protein concentration, and involve-
ment of deep brain structures (periventricular regions,
basal ganglia, brain stem, and/or cerebellum) are signifi-
cantly associated with a poor prognosis. This scoring
system was validated in patients treated with high-dose
methotrexate-based chemotherapy [3]. In contrast, the
Nottingham/Barcelona score, which incorporates age
≥60, PS ≥ 2 and multifocal disease, showed a prognostic
impact in patients treated with CHOD/BVAM or BVAM
chemotherapy followed by radiotherapy [4]. Meanwhile,
the Memorial Sloan-Kettering Cancer Center (MSKCC)
prognostic model is able to classify patients into class 1
(age ≤50 years), class 2 (age >50; Karnofsky performance
score (KPS) ≥70) and class 3 (age >50; KPS <70) with
prognostic significance [5]. However, there is still no
consensus about prognostic scoring systems in PCNS-
DLBCL. Moreover, the pathological and biological
prognostic factors for PCNS-DLBCL remain unknown.
Recent studies have shown that concomitant MYC and
BCL2 expression predicts inferior survival in systemic
DLBCL patients treated with rituximab-CHOP [6, 7].
Moreover, coexpression MYC and BCL2 was found to have
prognostic value in patients with DLBCL independent of
cell of origin, but is related to a high-risk gene expression
signature [7]. Thus, MYC and BCL2 coexpression status is
very helpful for risk stratification along with the inter-
national prognostic index (IPI) score in systemic DLBCL
[6, 7]. Meanwhile, only a few studies are available on MYC
and BCL2 expression in PCNS-DLBCL [8–10]. However,
these studies have demonstrated conflicting results in
terms of prognostic significance of MYC and BCL2 status
in patients with PCNS-DLBCL. A study on 47 patients
with PCNS-DLBCL showed that MYC, BCL2 and BCL6
were frequently coexpressed but had no prognostic signifi-
cance [8]. Another study demonstrated that MYC expres-
sion, with or without BCL2 coexpression, was not
predictive of clinical outcome in 59 patients with PCNS-
DLBCL [9]. In contrast, MYC expression was associated
with poor prognosis in a study on 42 patients with PCNS-
DLBCL [10]. Thus, we comprehensively investigated the
expression of MYC, BCL2 and BCL6, and their association
with clinicopathological characteristics and prognosis in a
large cohort of PCNS-DLBCL patients.
Methods
Patients
In total, 114 patients diagnosed with PCNS-DLBCL
managed at Seoul National University Hospital (SNUH,
Seoul, Korea) between 2000 and 2012 were included in
this study. Pathologic diagnosis was performed accord-
ing to the current World Health Organization (WHO)
classification of Tumors of Hematopoietic and Lymph-
oid Tissues [1]. Tumor tissues were obtained before
treatment in all patients. Clinicopathological and sur-
vival data were retrieved from medical records by three
hemato-oncologists (E.L, T.M.K and D.S.H) and from
the review of pathological material by three pathologists
(S.K., S.J.N and Y.K.J). This study followed the World
Medical Association Declaration of Helsinki recommen-
dations and was approved by the Institutional Review
Board (IRB) of SNUH (IRB No. 1506-080-681). Informed
consent for participation in the study was waived by the
IRB of SNUH on the basis that this study was a retro-
spective study using archived material and did not pose
increased risk to the patients.
Immunohistochemistry
Immunohistochemistry (IHC) was performed using anti-
bodies against MYC (clone EP121, Cell Marque, Rocklin,
CA, USA), BCL2 (clone 124, DAKO, Carpinteria, CA,
USA), BCL6 (clone LN22, Novocastra, Newcastle,
United Kingdom), CD10 (clone 56C6, Novocastra), and
MUM1 (clone Ma695, Novocastra). IHC staining was
performed using the Ventana Benchmark XT system
(Ventana Medical Systems, Tucson, AZ, USA) or a
Bond-Max automated immunostainer (Leica Microsys-
tems, Melbourne, Australia). Cell of origin was assessed
according to the Hans criteria [11]. IHC score was deter-
mined to be the percentage of tumor cells with robust
immunostaining evaluated by 10 % increments. Cutoff
values (i.e. IHC scores) of ≥40 % for MYC, ≥30 and
≥60 % for BCL2 and ≥50 % for BCL6 were determined
to have discriminant prognostic power based on the
receiver operator characteristic (ROC) curves and were
thus used for classifying cases into MYC-, BCL2- or
BCL6-negative and-positive groups.
Statistical analysis
A comparison of clinicopathological parameters was per-
formed by Chi-square, Fisher’s exact, and Student’s t-tests.
PFS and OS were analyzed using the Kaplan-Meier
method and the log-rank test. Univariate and multivariate
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analysis were performed using the Cox proportional haz-
ards regression model. All statistical analyses were per-
formed using SPSS software (version 21; IBM Corp.,
Armonk, NY, USA). Two-sided P values <0.05 were
considered statistically significant.
Results
Clinicopathological features of patients with PCNS-DLBCL
The clinicopathological characteristics and treatment mo-
dalities of 114 patients with PCNS-DLBCL are summarized
in Table 1. The patient population included 65 (57.0 %)
males and 49 (43.0 %) females with a median age of 61 years
(range 10–82 years). Most patients had experienced neuro-
logic deficits as the initial symptom (78/114, 68.4 %), and
had a KPS score ≥70 (97/111, 87.4 %) and an ECOG PS <2
(73/112, 65.2 %) at diagnosis. Deep structure involvement
(84/114, 73.7 %) and multifocality (72/114, 63.2 %) were fre-
quently observed. The majority (89/113, 78.8 %) of cases
were of non-germinal center B-cell origin, which was
higher than in systemic DLBCL patients in our institute
(63 %) [12]. In total, 52.7 % (48/91) of patients had an
IELSG score ≥ 3, 52.7 % (59/112) of patients had a
Nottingham-Barcelona score ≥2 and 79.8 % (91/112) of pa-
tients were classified as MSKCC class 2 or 3. Most patients
received high-dose methotrexate-containing chemotherapy
including high-dose methotrexate, vincristine and procar-
bazine (MVP) (79/97, 81.4 %) or high-dose methotrexate
(HD-MTX) (14/97, 14.4 %), and 58.8 % (57/97) of patients
were treated with combined MVP and radiotherapy.
The five-year PFS and OS based on clinicopathological
variables are shown in Table 1. Older patients (age >60)
had a shorter OS (P = 0.014), and patients with KSP <70
and multifocal lesions had a shorter PFS (P = 0.001 and
0.037, respectively). The non-germinal center phenotype
tended to have a poorer PFS, but this did not reach statis-
tical significance (P = 0.073). Patients with a Nottingham-
Barcelona score ≥2 or MSKCC class 2 or 3 had a shorter
PFS (P = 0.001 and 0.008, respectively). The IELSG scoring
system showed inconclusive results, in that patients with an
IELSG score ≥3 had a tendency to show better PFS (P =
0.093) and worse OS (P = 0.054). The treatment modalities
including the chemotherapeutic agent, use of radiotherapy,
rituximab or intrathecal-MTX were not associated with pa-
tient clinical outcomes in the total patient group. However,
in the MVP-treated group, patients receiving radiotherapy
showed a better prognosis than did those who did not
receive radiotherapy (for PFS, P = 0.078; for OS, P = 0.001)
(data not shown).
Relationship between MYC, BCL2, and BCL6 expression
and clinicopathological features
Representative IHC images of MYC, BCL2 and BCL6
are shown in Fig. 1. The proportion of tumor cells
expressing MYC (i.e., MYC IHC score) was estimated
as 18.16 ± 19.58 % (mean ± SD) (median: 10, range: 0-
80 %). Using a cutoff score of 40, 21 (18.1 %) of the
114 cases were placed in the MYC-positive group.
The BCL2 IHC score was also measured, with an
average score of 58.86 ± 35.07 % (median: 70, range:
0-100 %); 87 (75.0 %) and 68 (59.6 %) of the 114
cases were classified as BCL2-positive using cutoff
score of 30 and 60, respectively. The average BCL6
IHC score was 39.39 ± 37.66 % (median: 25, range: 0–
100 %), and 51 (44.0 %) of the 114 cases were classi-
fied as BCL6-positive using a cutoff score of 50.
Taken together, MYC and BCL2 dual-positive cases
accounted for 15.8 % (18/114) of PCNS-DLBCLs,
while MYC and BCL2 dual-negative cases accounted
for 21.9 % (25/114) with a BCL2 cutoff score of 30.
In addition, MYC and BCL2 IHC scores were posi-
tively correlated (Spearman’s rho = 0.320, P = 0.001),
but MYC and BCL6, and BCL2 and BCL6 IHC scores
were not (Additional file 1: Figure S1).
Among the 57 patients treated with combined MVP
and radiotherapy (MVP-RT hereafter), 12.3 % (7/57)
were designated as MYC-positive using a cutoff score
of 40, and 71.9 % (41/57) and 54.4 % (31/57) of the
cases were classified as BCL2-positive using cutoff
scores of 30 and 60, respectively; 49.1 % (28/57) of the
cases were classified as BCL6-positive using a cutoff
score of 50. Taken together, MYC and BCL2 dual-
positive cases accounted for 12.3 % (7/57; with a BCL2
cutoff score of 30) and 10.5 % (6/57; with a BCL2 cut-
off score of 60), while MYC and BCL2 dual-negative
cases accounted for 28.1 % (16/57; with a BCL2 cutoff
score of 30) and 43.9 % (25/57; with a BCL2 cutoff
score of 60) of patients in the MVP-RT group.
The relationship between MYC, BCL2 and BCL6
expression and clinicopathological features are sum-
marized in Table 2 and Additional file 2: Table S1.
Patients aged > 60 years tended to be BCL2-positive
more often (P = 0.051), and higher MSKCC class was
significantly associated with MYC and BCL2 positivity
separately (P = 0.012 and 0.008, respectively) (Table 2)
and with MYC and BCL2 coexpression (P = 0.022 by
Fisher’s Exact Test) (data not shown). Cases of non-
germinal cell origin were BCL2-positive more often
(P = 0.005), but were BCL6-negative (P = 0.013)
(Table 2 and Additional file 2: Table S1). There were
no other correlations between clinical parameters and
MYC, BCL2 or BCL6 expression. In addition, MYC,
BCL2 or BCL6 positivity did not differ by treatment
modality (data not shown). Among the patients of
MVP-RT group, no significant relationship was
observed between clinicopathological features and the
MYC and BCL2 expression status except for higher
expression of MYC in female than in male (P = 0.039)
(data not shown).
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Table 1 Clinicopathological characteristics of patients and treatment modalities
Variablesa n (%) 5YRS PFS,
Pd
5YRS OS,
Pd(Total = 114) PFS (SD) OS (SD)
Age (yr) ≤50 23 (20.2) 0.684 (0.108) 0.072 0.909 (0.043) 0.126
>50 91 (79.8) 0.334 (0.090) 0.698 (0.086)
Age (yr) ≤60 55 (48.2) 0.498 (0.081) 0.585 0.854 (0.065) 0.014
>60 59 (51.8) 0.217 (0.167) 0.569 (0.172)
Sex M 65 (57.0) 0.452 (0.086) 0.708 0.849 (0.054) 0.156
F 49 (43.0) 0.460 (0.112) 0.452 (0.168)
Initial Symptoms Headache &vomiting 30 (26.3) 0.609 (0.114) 0.400 0.870 (0.071) 0.266
Seizure 6 (5.3) 0.000 (0.000) 100.0
Neurologic deficit 78 (68.4) 0.387 (0.085) 0.697 (0.085)
ECOG PS 0, 1 73 (65.2) 0.425 (0.086) 0.818 0.789 (0.075) 0.247
2–4 39 (34.8) 0.511 (0.135) 0.752 (0.079)
KPS ≥70 97 (87.4) 0.468 (0.082) 0.001 0.760 (0.065) 0.854
<70 14 (12.6) 0.259 (0.144) 0.821 (0.117)
B Symptoms Absent 109 (95.6) 0.452 (0.073) 0.284 0.768 (0.061) 0.558
Present 5 (4.4) 0.333 (0.272) 0.800 (0.179)
Serum LDH Normal 68 (63.6) 0.223 (0.087) 0.005 0.767 (0.102) 0.201
Elevated 39 (36.4) 0.675 (0.102) 0.760 (0.100)
Cell of origin GCB 24 (21.2) 0.689 (0.120) 0.073 0.795 (0.092) 0.957
Non-GCB 89 (78.8) 0.383 (0.082) 0.756 (0.074)
Involvement of deep structure Absent 30 (26.3) 0.441 (0.161) 0.219 0.758 (0.129) 0.640
Present 84 (73.7) 0.433 (0.078) 0.762 (0.070)
Extent of disease Unifocal 42 (36.8) 0.553 (0.119) 0.037 0.753 (0.137) 0.603
Multifocal 72 (63.2) 0.368 (0.088) 0.782 (0.062)
Ocular involvement Absent 101 (89.4) 0.485 (0.072) 0.985 0.872 (0.046) 0.466
Present 12 (10.6) 0.233 (0.190) 0.525 (0.204)
CSF protein Normal 39 (42.4) 0.291 (0.142) 0.988 0.675 (0.141) 0.340
Elevated 53 (57.6) 0.467 (0.090) 0.849 (0.058)
CSF cytology Negative 82 (85.4) 0.356 (0.083) 0.281 0.774 (0.066) 0.693
Positive 14 (14.6) 0.608 (0.158) 0.711 (0.180)
IELSG 0–2 43 (47.3) 0.229 (0.100) 0.093 0.853 (0.101) 0.054
3–5 48 (52.7) 0.638 (0.088) 0.736 (0.074)
Nottingham– Barcelona 0–1 53 (47.3) 0.604 (0.097) 0.001 0.807 (0.080) 0.188
2–3 59 (52.7) 0.264 (0.098) 0.723 (0.084)
MSKCC class 1 21 (18.4) 0.760 (0.106) 0.008 0.847 (0.108) 0.157
2–3 91 (79.8) 0.340 (0.086) 0.688 (0.095)
Radiotherapy Not done 36 (31.6) 0.586 (0.142) 0.854 0.758 (0.086) 0.057
Done 78 (68.4) 0.416 (0.080) 0.787 (0.068)
Chemotherapy MVPb 79 (81.4) 0.431 (0.084) 0.519 0.772 (0.072) 0.940
HD-MTX 14 (14.4) 0.442 (0.176) 0.791 (0.138)
Othersc 4 (4.1) 0.750 (0.217) 100.0
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Prognostic significance of MYC, BCL2 and BCL6
expression
Kaplan-Meier survival analysis demonstrated that MYC
expression (cutoff score 40) was significantly associated
with a shorter PFS (P = 0.027) in patients with PCNS-
DLBCL (Fig. 2a), but not with OS (Fig. 2b). In contrast,
higher BCL2 expression was significantly related to a
shorter OS (P = 0.010 with a cutoff score of 30 and P =
0.031 with a cutoff score 60), but was not related to PFS
(Fig. 2c-f). BCL6 expression had no prognostic signifi-
cance. Patients who were negative for both MYC and
BCL2 (cutoff score 30) showed better OS than patients
positive for either (P = 0.014) (Fig. 3a and b). Patients
with dual positivity for MYC and BCL2 (cutoff score 30)
exhibited worse PFS than that of the others (P = 0.041)
(Fig. 3c and d), but its statistical significance was lower
than that observed by comparing MYC expression status
alone (Fig. 2a). After incorporating both age and prog-
nostic score into a multivariate analysis, MYC and BCL2
expression lost its prognostic impact, and a higher
Nottingham-Barcelona score (≥2) and age remained as
independent prognostic indicators for PFS (P = 0.032)
and OS (P = 0.044), respectively (Table 3).
Among patients with PCNS-DLBCL treated with MVP-
RT, MYC expression (cutoff score of 40) was associated
with a shorter PFS (P = 0.011) (Additional file 3: Figure S2).
BCL2 overexpression (cutoff score of 60) was significantly
related to a shorter OS (P = 0.025) (Additional file 3: Figure
S2). In the MVP-RT group, patients with dual positivity for
MYC and BCL2 (cutoff score of 60) exhibited worse PFS
than that of the others (P <0.001) (Fig. 3e), and those who
were negative for both MYC and BCL2 (cutoff score of 60)
showed better OS than that of patients positive for either
(P = 0.033) (Fig. 3f). Furthermore, in multivariate analysis,
MYC and BCL2 coexpression was an independent factor
for poor PFS (P = 0.010; hazard ratio = 4.372) (Table 4).
Discussion
This study demonstrated that MYC and BCL2 overex-
pression was significantly associated with a high MSKCC
class, and was related to shorter PFS and OS in patients
with PCNS-DLBCL.
Table 1 Clinicopathological characteristics of patients and treatment modalities (Continued)
Rituximab Not done 103 (90.4) 0.453 (0.074) 0.756 0.748 (0.067) 0.503
Done 11 (9.6) 0.333 (0.248) 0.909 (0.087)
IT-MTX Not done 89 (78.1) 0.412 (0.092) 0.649 0.743 (0.076) 0.415
Done 25 (21.9) 0.457 (0.114) 0.832 (0.089)
Abbreviations: ECOG PS The Eastern Cooperative Oncology Group performance score, KPS Karnofsky performance status score, LDH lactate dehydrogenase, GCB
germinal center B cell-like, CSF cerebrospinal fluid, IELSG the International Extranodal Lymphoma Study group, MSKCC Memorial Sloan Kettering Cancer Center,
MVP combined chemotherapy regimen of high-dose methotrexate, vincristine and procarbazine, HD-MTX high-dose methotrexate, IT-MTX intrathecal methotrexate,
PFS progression-free survival, OS overall survival
aSome cases have missing values that lacked the information about the variables
bIncludes 8 patients who received rituximab-MVP
cOthers include COPADM and CHOP
dPFS and OS were analyzed using the Kaplan-Meier method with the log-rank test
Fig. 1 Representative immunohistochemical images of MYC, BCL2 and BCL6 expression in PCNS-DLBCL tumors. Representative IHC images of
MYC-negative (A-1) and -positive (A-2) cases, BCL2-negative (B-1) and -positive (B-2) cases, and BCL6-negative (C-1) and -positive (C-2) cases
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This study showed that MYC overexpression was
associated with poor PFS in PCNS-DLBCL, which
was partly consistent with Tapia et al.’s study [10],
but different from previous reports by Brunn et al.
and Gill et al. [8, 9]. Tapia et al. reported that MYC
overexpression (using a cutoff score of 30) was re-
lated to poor OS, while the latter studies showed that
MYC expression was not associated with PCNS-
DLBCL prognosis. In this study, the mean MYC
expression score was 18.16 ± 19.58 and the MYC posi-
tive rate using a cutoff score of 40 was 18.1 %, which
were much lower than those observed in previous re-
ports. Previous studies on PCNS-DLBCL reported a
mean MYC expression score of 29–50 and MYC posi-
tive rates ranging from 43 to 82 % with cutoff values
of 30 or 40, and an unreported cutoff score in one
Table 2 Correlation of MYC and BCL2 expression and clinicopathological variables
MYC, n (%) BCL2, n (%)
Variablesa <40 ≥40 P <30 ≥30 P
Age (yr) mean ± SD 57.6 ± 14.6 63.1 ± 7.6 0.097 50.4 ± 19 61.3 ± 10.4 <0.001
Age (yr) ≤50 22 (95.7) 1 (4.3) 0.069 11 (47.8) 12 (52.2) 0.004
>50 71 (78) 20 (22) 17 (18.7) 74 (81.3)
Age (yr) ≤60 46 (83.6) 9 (16.4) 0.584 18 (32.7) 37 (67.3) 0.051
>60 47 (79.7) 12 (20.3) 10 (16.9) 49 (83.1)
Sex M 55 (84.6) 10 (15.4) 0.335 20 (30.8) 45 (69.2) 0.076
F 38 (77.6) 11 (22.4) 8 (16.3) 41 (83.7)
ECOG PS 0, 1 62 (84.9) 11 (15.1) 0.172 19 (26) 54 (74) 0.731
2–4 29 (74.4) 10 (25.6) 9 (23.1) 30 (76.9)
KPS ≥70 81 (83.5) 16 (16.5) 0.136 24 (24.7) 73 (75.3) >0.999
<70 9 (64.3) 5 (35.7) 3 (21.4) 11 (78.6)
B symptoms Absent 88 (80.7) 21 (19.3) 0.582b 26 (23.9) 83 (76.1) 0.595b
Present 5 (100) 0 (0) 2 (40) 3 (60)
Serum LDH Normal 54 (79.4) 14 (20.6) 0.506 19 (27.9) 49 (72.1) 0.582
Elevated 33 (84.6) 6 (15.4) 9 (23.1) 30 (76.9)
Cell of origin GCB 22 (91.7) 2 (8.3) 0.236b 11 (45.8) 13 (54.2) 0.005
Non-GCB 70 (78.7) 19 (21.3) 16 (18) 73 (82)
Involvement of deep structure Absent 24 (80) 6 (20) 0.795 6 (20) 24 (80) 0.499
Present 69 (82.1) 15 (17.9) 22 (26.2) 62 (73.8)
Extent of disease Unifocal 34 (81) 8 (19) 0.895 11 (26.2) 31 (73.8) 0.758
Multifocal 59 (81.9) 13 (18.1) 17 (23.6) 55 (76.4)
Ocular involvement Absent 82 (81.2) 19 (18.8) >0.999b 25 (24.8) 76 (75.2) >0.999b
Present 10 (83.3) 2 (16.7) 3 (25) 9 (75)
CSF protein Normal 31 (79.5) 8 (20.5) 0.844 8 (20.5) 31 (79.5) 0.157
Elevated 43 (81.1) 10 (18.9) 18 (34.0) 35 (66.0)
CSF cytology Negative 66 (80.5) 16 (19.5) >0.999b 19 (23.2) 63 (76.8) 0.121
Positive 11 (78.6) 3 (21.4) 6 (42.9) 8 (57.1)
IELSG 0–2 35 (81.4) 8 (18.6) 0.790 13 (30.2) 30 (69.8) 0.740
3–5 38 (79.2) 10 (20.8) 13 (27.1) 35 (72.9)
Nottingham- Barcelona 0–1 46 (86.8) 7(13.2) 0.154 16 (30.2) 37 (69.8) 0.229
2–3 45 (76.3) 14 (23.7) 12 (20.3) 47(79.7)
MSKCC class 1 21 (100) 0 (0) 0.012b 10 (47.6) 11 (52.4) 0.008
2–3 70 (76.9) 21 (23.1) 18 (19.8) 73 (80.2)
Abbreviations: ECOG PS The Eastern Cooperative Oncology Group performance score, KPS Karnofsky performance status score, LDH lactate dehydrogenase, GCB
germinal center B cell-like, CSF cerebrospinal fluid, IELSG the International Extranodal Lymphoma Study group, MSKCC Memorial Sloan Kettering Cancer Center
aSome cases have missing values that lacked the information about the variables
bFisher’s exact test
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case [8–10]. However, antibody and racial differences
(Western vs. Asian) may account for these discrepancies.
MYC immunostaining in systemic DLBCLs, particu-
larly in cases without MYC gene translocation, is hetero-
geneous. Thus, the feasibility of interpreting and scoring
MYC expression using IHC in DLBCL has been ques-
tioned [13]. We performed MYC fluorescence in situ
hybridization in PCNS-DLBCL cases with MYC overex-
pression as reported previously [14]. Of note, in this study,
only 2 (12 %) of 17 patients with MYC overexpression had
a MYC translocation, and another two patients showed in-
creased MYC copy number (ICN) (Additional file 2: Table
S2). In contrast, approximately 25 % of the MYC overex-
pressing systemic DLBCLs showed MYC gene transloca-
tion [15]. Thus, translocation and ICN did not appear to
explain MYC overexpression in most cases of PCNS-
DLBCL, consistent with a previous report [10]. MYC over-
expression in PCNS-DLBCL might result from other
mechanisms such as a mutation of MYC and post-
transcriptional or post-translational regulation. In addition,
Fig. 2 Progression-free survival (PFS) and overall survival (OS) of patients with PCNS-DLBCL according to MYC or BCL2 expression status. a and b
PFS and OS according to MYC protein expression status (cutoff score 40) are plotted using the Kaplan-Meier method and analyzed by the log-rank test.
PFS and OS according to BCL2 protein expression status using a cutoff score of 30 (c and d), or with a cutoff score of 60 (e and f) are plotted using
the Kaplan-Meier method and analyzed by the log-rank test
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post-genetic or epigenetic regulation of MYC expression in
PCNS-DLBCL may lead to heterogeneous MYC immuno-
staining. Meanwhile, concordance of MYC scoring
between hematopathologists was much lower when inter-
preting entire tissue sections rather than a tissue micro-
array using a 1-mm core [13]. In this study, whole tissue
sections were used and the largest series of patients with
PCNS-DLBCL was evaluated based on treatment modality,
and MYC overexpression was found to have prognostic
value.
The rate of BCL2 expression in PCNS-DLBCL varies,
which might also be attributable to the use of different
antibodies and different cutoff values for determining
overexpression [8, 9, 16–19]. Previous studies reported a
wide range of BCL2 expression rates (56–92 %) with
various cutoff scores from 25–70. We observed that
Fig. 3 Progression-free survival (PFS) and overall survival (OS) of patients with PCNS-DLBCL according to combined MYC and BCL2 expression status. a
and b PFS and OS of patients without expression for either MYC or BCL2 (double-negative) versus other groups are plotted using the Kaplan-Meier method
and analyzed by the log-rank test. c and d PFS and OS of patients with concomitant MYC and BCL2 expression (double-positive) versus other groups are
plotted using the Kaplan-Meier method and analyzed by the log-rank test. e and f PFS and OS of patients treated with combined MVP and radiotherapy
according to the MYC and BCL2 expression status were plotted using the Kaplan-Meier method and analyzed by the log-rank test
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75.0 % (87/114) of PCNS-DLBCL cases were BCL2-
positive using a cutoff score of 30, similar to a previous
report by Tapia et al. [10]. In their study, BCL2 positivity
was observed in 71 % of PCNS-DLBCL cases, but had
no relationship with prognosis [10]. In contrast, the
present study demonstrated that patients with PCNS-
DLBCL and BCL2 overexpression tended to have a
shorter PFS and had significantly poorer OS, suggesting
that BCL2 may potentially be used as a prognostic
marker.
In this study, MYC and BCL2 expression lost their
prognostic significance after multivariate analysis. This
may be partly attributable to the fact that MYC and
BCL2 expression was significantly associated with
higher MSKCC class. The MYC and BCL2 coexpres-
sion rate was 15.8 % (18/114) of PCNS-DLBCLs, which
was much lower than values from previous studies
including 29 % (12/41), 60 % (35/59) and 82 % (41/50)
of PCNS-DLBCLs and 34 % (157/466) of systemic
DLBCLs [7–10], but was similar to the rate (21 % [64/
304]) reported in another study on systemic DLBCLs
[6]. In this study, patients with PCNS-DLBCL and con-
comitant MYC and BCL2 overexpression showed poor
PFS (P = 0.041), and those lacking both MYC and
BCL2 overexpression had a prolonged OS (P = 0.014).
However, the statistical significance of MYC and BCL2
dual-positivity on the PFS of patients was diminished
compared to MYC positivity alone (P = 0.027). Similar
to the present study, Tapia et al. reported that high
MYC expression was associated with a lower OS, but
that concurrent expression of MYC and BCL2 showed
a tendency towards a lower OS with no statistical sig-
nificance [10]. However, in this study, when analyzed
in patients with PCNS-DLBCL treated with combined
MVP and radiotherapy, MYC and BCL2 dual-positivity
was an independent prognostic factor for poor PFS.
Thus, MYC and BCL2 coexpression in PCNS-DLBCL
seems to have prognostic value, although it is limited
compared with systemic DLBCL.
Several previous studies are available on BCL6 ex-
pression and its prognostic impact on PCNS-DLBCL.
BCL6 expression rates from 46 to 79 % of PCNS-
DLBCL cases with cutoff scores from 10–60 have
been reported [16, 18, 20–22]. The prognostic impli-
cations of BCL6 for PCNS-DLBCL are largely con-
flicting [10, 16, 19–25]. The results of this study
further suggest that BCL6 may have little, if any,
prognostic value for PCNS-DLBCL. Non-GCB pheno-
type tumors were the predominant PCNS-DLBCL
type in this study, and no association between cell of
origin and prognosis was found, which is consistent
with previous reports [9, 26, 27]. Unexpectedly, pa-
tients with high serum LDH levels had a more favor-
able PFS than that of patients with normal serum
LDH levels. In addition, the results of this study show
that alleged prognostic scoring systems, including
Nottingham-Barcelona and MSKCC, reflect PFS but
not OS. The reason for these discrepancies is not
known, and we were unable to deduce the reasons
over the course of this study; however, these results
might support the idea that PCNS-DLBCL prognosis
is dependent on multiple, complex factors. This study
has some limitations. It was a retrospective study, and
therapeutic modalities were not completely homoge-
neous between patients. However, to the best of our
knowledge, this study is the largest performed on the
expression of MYC, BCL2 and BCL6 PCNS-DLBCL
with long-term follow up, and the first report on the
Table 3 Multivariate analysis of MYC expression and prognostic scoring systems for progression-free survival and overall survival in
all patients with PCNS-DLBCL
PFS OS
HR 95 % CI P HR 95 % CI P
Age 0.989 0.949-1.032 0.614 Age 1.074 1.002–1.151 0.044
MYC≥ 40 1.745 0.848–3.589 0.130 BCL2≥ 30 -a -a 0.951
N-B, 2-3 2.243 1.072–4.693 0.032 N-B, 2-3 1.392 0.474–4.084 0.547
MSKCC, 2–3 2.635 0.502–13.827 0.252 MSKCC, 2–3 0.370 0.048–2.841 0.339
Abbreviations: PFS progression-free survival, OS overall survival, HR hazard ratio, CI confidence interval, N-B Nottingham-Barcelona, MSKCC Memorial Sloan Kettering
Cancer Center
(avalues are not shown.)
Table 4 Multivariate analysis of MYC and BCL2 coexpression
and prognostic scoring systems for progression-free survival in
patients with PCNS-DLBCL treated with combined MVP and
radiotherapy
PFS
HR 95 % CI P
Age 0.983 0.922–1.049 0.605
N-B, 2–3 1.146 0.464–2.830 0.768
MSKCC, 2–3 4.975 0.715–34.613 0.105
MYC (≥40) and BCL2 (≥60), dual positive 4.372 1.430–13.367 0.010
Abbreviations: PFS progression-free survival, HR hazard ratio, CI confidence
interval, N-B Nottingham- Barcelona, MSKCC Memorial Sloan Kettering
Cancer Center
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relationship of these factors to clinicopathological fea-
tures in Asian patients.
Conclusions
This study demonstrated that the expression of MYC
and BCL2 may be of prognostic value in patients with
PCNS-DLBCL when combined with existing prognostic
tools and factors.
Additional files
Additional file 1: Figure S1. Correlation of MYC, BCL2 and BCL6 IHC
score. Correlations between MYC and BCL2 (left upper), MYC and BCL6
(right upper), and BCL2 and BCL6 (lower) IHC score was compared using
Spearman correlation test. (PPT 343 kb)
Additional file 2: Table S1. Correlation of BCL6 expression and
clinicopathological variables; Table S2. MYC translocation and copy
number change in MYC positive cases. (DOCX 24 kb)
Additional file 3: Figure S2. Progression-free survival (PFS) and overall
survival (OS) of patients with PCNS-DLBCL treated with MVP-RT according
to MYC or BCL2 expression status. (A and B) PFS and OS according to
MYC protein expression status (cutoff score 40) are plotted using the
Kaplan-Meier method and analyzed by the log-rank test. PFS and OS
according to BCL2 protein expression status using a cutoff score of 30
(C and D), or with a cutoff score of 60 (E and F) are plotted using the
Kaplan-Meier method and analyzed by the log-rank test. (TIF 12287 kb)
Additional file 4: Dataset of 114 patients with PCNS-DLBCL. (XLSX 56 kb)
Abbreviations
CHOD/BVAM, cyclophosphamide, doxorubicin, vincristine and dexamethasone/
bis-chloronitrosourea, cytosine arabinoside and methotrexate; CHOP,
cyclophosphamide, doxorubicin, vincristine and prednisone; CI, confidence
interval; CNS, central nervous system; COPADM, cyclophosphamide, vincristine,
prednisolone, doxorubicin and methotrexate; CSF, cerebrospinal fluid; DLBCL,
diffuse large B-cell lymphoma; ECOG PS, The Eastern Cooperative Oncology Group
performance score; GCB, germinal center B-cell-like; GTR, grossly total resection;
HD-MTX, high-dose methotrexate; HR, hazard ratio; IELSG, The international
extranodal lymphoma study group; IHC, immunohistochemistry; IPI, international
prognostic index; IT-MTX, intrathecal methotrexate; KPS, Karnofsky Performance
Status score; LDH, lactate dehydrogenase; MSKCC, Memorial Sloan-Kettering
Cancer Center; MVP, combined chemotherapy regimen of high-dose methotrexate,
vincristine and procarbazine; N-B, Nottingham- Barcelona; OS, overall survival; PCNS-
DLBCL, primary diffuse large B-cell lymphoma of the central nervous system; PFS,
progression-free survival; RT, radiotherapy; STR, subtotal resection; WHO, World
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